University Of California San Francisco
American Association for Cancer Research names academy fellows
ID physicians define new role in opioid crisis
Ixabepilone remains inferior to paclitaxel in metastatic disease
RISE registry reveals widespread MIPS score disparity for rheumatologists

SAN DIEGO — Quality measurements reported by rheumatology practices through the RISE registry varied widely in performance during the first quarter of 2017, which could result in fiscal consequences through the new Merit-Based Incentive Payment System, according to findings presented at the American College of Rheumatology Annual Meeting.
California law may minimally impact drug pricing transparency
Travel medicine and ID: Partners in an era of frequent global movement

Travel history has a profound and essential role for the infectious disease clinician and for promoting public health priorities. The patient’s lifetime of geographic exposures, and especially those in the most recent few months, will determine what potential diagnoses are included in the differential diagnosis, whether caring for a patient with a fever, a skin lesion, a pulmonary infiltrate, focal neurologic lesion or other problem. A person’s geographic exposure profile must be combined with the clinician’s knowledge (or access to information) about clinical presentations, incubation periods, frequency of occurrence, and geographic distribution of dozens of common and a few hundred uncommon infections.
Debate: Benefits, harms of social media sharing from medical conferences
Breast cancer survivors diagnosed at younger age show higher risk for colon cancer
Multitasking, silent EHR use affect patient care
Guest Commentary: STAMPEDE trial provides exciting results, questions in prostate cancer treatment

In this guest commentary, Terence Friedlander, MD, discusses the benefits associated with the addition of abiraterone acetate to standard treatment in patients with high-risk advanced prostate cancer and the challenges facing the community , following a presentation of the STAMPEDE trial delivered at the ASCO Annual Meeting by Nicholas James, BSc, MBBS, PhD, from Queen Elizabeth Hospital in Birmingham, United Kingdom . Friedlander is an assistant clinical professor at the division of hematology/oncology at UCSF’s Helen Diller Family Comprehensive Cancer Center .